ClinicalTrials.gg
RecruitingNCT07331987Updated Jun 29, 2026

Efficacy and Safety of Probiotics for Anxiety Depression

An interventional study of Probiotic and Placebo in Anxiety Depression, sponsored by Moon (Guangzhou) Biotechnology Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-06-29.

Sponsored by Moon (Guangzhou) Biotechnology Co., Ltd. · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 358 studies in Depression with a site in China — 119 open to participants now, 138 under way, 3 of them phase 3. Depression · China.

Planned enrollment
212th of 284
60 · median 129
Started
2026
with 37 others
No phase
218 of 358
71 open now
Primary completion
2026-12
later than 79 of 137 live
Registered
314th of 358
by date

Among the 358 studies in Depression with a site in China, this one is the 212th largest by planned enrollment of the 284 interventional ones that give a count, is one of 38 that started in 2026, is one of 218 with no phase, reaches primary completion later than 79 of the 137 other live ones, and was the 314th registered.

Depression

8,595 studies on the registry are indexed under Depression; 1,728 are open to participants now.

Browse Depression studies →

Open to participants now

119 of the 358 studies in Depression with a site in China are open now. Recruiting first, the newest first:

113 more — sign in →

All 119 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,090 Depression studies recruiting now, 470 (43%) set no upper age limit and 520 (48%) stop at 75 or younger; 203 take children under 18; 311 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 358 studies in Depression with a site in China, or all of them as a file.
02

Study summary

This randomized, double-blind, placebo-controlled study will enroll 60 individuals with mild-to-moderate anxiety depression. Following a 3-month intervention and a 1-month follow-up period, the study aims to: 1) evaluate the efficacy of probiotics by comparing anxiety, depression, and sleep scores to baseline; and 2) investigate the safety and underlying mechanisms by analyzing changes in serum biomarkers, gut microbiota, and related metabolites.

03

Conditions studied

  • Anxiety Depression

Keywords

  • Depression
  • Anxiety
  • Mood
  • Probiotics
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1) Age: 18-60 years old; Gender: male or female.
  • 2) Meets the diagnostic criteria of , Fifth Edition (DSM-5) for a mild-to-moderate depressive or anxiety symptoms.
  • 3) Hamilton Depression Rating Scale (HAM-D-24) score ≥ 8 or Hamilton Anxiety Rating Scale (HAM-A-14) score ≥ 7 at screening.
  • 4) Has no used of anxiolytic or antidepressant medications (including traditional Chinese patent medicines), with the exception of Escitalopram Oxalate, within 2 weeks prior to the first dose.
  • 5) For participants of (male or female): Must agree to use least one medically approve form of (e.g., intrautering device [IUD], oral contraceptives, or condoms) throughout the trial. For female participants of childbearing potential: Must have a negative urine pregnancy test at screening and must be non-lactating.
  • 6) The participant is willing and be able to provide written to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • 1) HAM-D-24 score ≥ 35 or HAM-A-14 score ≥ 29.
  • 2) Presence of significant suicidal ideation.
  • 3) History or current diagnosis of neuropsychiatric disorders such as schizophrenia or epilepsy.
  • 4) History of head trauma (with loss of consciousness for >10 minutes), other unstable major somatic diseases, or any somatic condition that could cause psychiatric symptoms.
  • 5) Suspected intellectual disability.
  • 6) History of alcohol or substance abuse prior to enrollment.
  • 7) Cranial magnetic resonance imaging (MRI) reveals organic lesions.
  • 8) Participants who are deemed unsuitable for the study by the investigator for any other reason.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Placebo comparator
    Placebo + Escitalopram

    Drug: Placebo · Combination Product: Escitalopram

  • Experimental
    Probiotics + Escitalopram

    Drug: Probiotic · Combination Product: Escitalopram

Interventions

  • Participants receive Probiotic product once daily by oral, 60B CFU/day for 3 months.

  • DrugPlacebo

    Participants receive Placebo once daily by oral for 3 months.

  • Combination productEscitalopram

    Participants receive Escitalopram Oxalate Tablets once daily by oral, 10mg/day for 3 months.

06

What researchers measure

Primary outcomes

  1. Hamilton Depression Rating Scale (HAM-D-24)

    Depression symptoms will be assessed using the 24-item Hamilton Depression Rating Scale (HAM-D-24) at baseline and the specified time points during the study. With higher scores indicating more severe depression, and scores categorized as \<8 non-depressed, 8-19 mild, 20-34 moderate, ≥35 severe for diagnosis and monitoring treatment response.

    Time frame: Baseline, Day 30, Day 90, Day 120 (follow up)

  2. Hamilton Anxiety Rating Scale (HAM-A)

    Anxiety symptoms will be evaluated using 14-item Hamilton Anxiety Rating Scales (HAM-A) at baseline and the specified time point during the study. Each item is scored on a scale of 0 (not present) to 4 (severe). The total score, calculated by summing all items, ranges from 0 to 56, with higher scores indicating greater anxiety severity, where 0-7 indicates no/minimal, 8-14 mild, 15-23 moderate and ≥24 severe.

    Time frame: Baseline, Day 30, Day 90, Day 120 (follow up)

Secondary outcomes

  1. The Pittsburgh Sleep Quality Index (PSQI)

    Assesses sleep quality from baseline to end of the study by questionnaire of The Pittsburgh Sleep Quality Index (PSQI). There are 19 items that are used to generate 7 component scores, which then are added together to determine a global score that ranges between 0 to 21, where higher scores reflect worse sleep quality.

    Time frame: Baseline, Day 30, Day 90, Day 120 (follow up)

  2. Gastrointestinal Symptom Rating Scale (GSRS)

    Assessment of gastrointestinal symptoms will conducted at baseline and throughout the study period. The GSRS is a disease-specific instrument of 15 items combined into five symptom clusters depicting Reflux, Abdominal pain, Indigestion, Diarrhoea and Constipation. The GSRS has a seven-point graded Likert-type scale where 1 represents absence of troublesome symptoms and 7 represents very troublesome symptoms.

    Time frame: Baseline, Day 30, Day 90, Day 120 (follow up)

07

Study locations

1 of 1 sites recruiting
  • The First Affiliated Hospital of Guangdong Pharmaceutical University
    Guangzhou, Guangdong, China
    Recruiting
    • IRB, First Affiliated Hosp, Guangdong Pharm Univ · Contactgylunli@163.com · 86-020-87609616
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Dec 2026, 6 months after the start.

Of 98 industry-sponsored interventional studies with no phase under Depression, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's planned 6 months is below that.

Counting every sponsor, half of 3,574 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 30, 2025
First posted
Jan 12, 2026
StartActual
Jun 15, 2026
Primary completionEst.
Dec 30, 2026
CompletionEst.
Feb 28, 2027
Last update
Jun 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07331987
Lead sponsor
Moon (Guangzhou) Biotechnology Co., Ltd.
Responsible party
Sponsor
First posted
Jan 12, 2026
Start date
Jun 15, 2026
Primary completion
Dec 30, 2026 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Jun 29, 2026

Study contacts

Baojia Huang
Contact
huangbj@moonbio.com
86-020-31603387

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Probiotic

Start the discussion